Sponsor study identifier
Secondary identifiers
interventional
650
1 country
1
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
Not reported
Date not reportedStudy Completion
December 2004
Actual (reported)Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2004
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
December 2004
Actual (reported)September 8, 2005
Actual (reported)September 12, 2005
Actual (reported)Day 7 slide clearance rate (complete clearance of trophozoites) assessed by microscopists who are blind to treatment allocation.
Day 28 slide clearance rate without subsequent recrudescence.
Day 7 gametocyte prevalence.
Day 14 gametocyte prevalence
Fever clearance time
cure rate (elimination of parasitaemia without recrudescence).
Rate and time of parasite clearance.
Rate of resolution of fever.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
These entries preserve how the registry describes the intervention. Their treatment roles are shown separately from molecular identities.
Grouped treatment entry
SP, chloroquine, amodiaquine, primaquine, artesunate
The registry names several treatments. This does not confirm that participants received them together or that they form a single product.
View registry recordHealthNet International
Peshawar, Pakistan
Kate Graham, MSc
HealthNet International, Peshawar, Pakistan
650 participants (actual enrollment reported by the registry).
First Submitted
September 8, 2005
First Posted
September 12, 2005
Study Start
June 2001
Date type not reportedThis date has not been verified as actual or estimated.
Intermittent Preventative Treatment With Sulfadoxine-Pyrimethamine in Gambian Multigravidae
Contact the study team to confirm eligibility.
Study Completion
December 2004
Actual (reported)Last Updated
January 12, 2017
Record last verified: 2017-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: